Business Wire

ORAL-B

Share
Oral-B Encourages Consumers to Brush up on Their Oral Care Regimen and Recognise Its Importance to Overall Body Health

Oral-B has teamed up with Scientific American and its Custom Media Division (SACM) to explore the latest research connecting oral health and overall health; as many are unaware of the impact chronic periodontal diseases have on wider systemic disease.

The brand is leading the way in innovation, technology and research to help protect oral health and educate about the important connection between oral and overall body health. As part of the year-long partnership, Oral-B and Scientific American Custom Media are releasing a series of content, including educational resources from leading medical and dental researchers that will help readers better understand the connections between oral health and whole body health.

Oral diseases are at crisis level as it is estimated that they affect nearly 3.5 billion people worldwidei and in the midst of a global health pandemic, it is more crucial than ever to safeguard not only your oral health but your whole-body health too.

Jeremy A. Abbate, VP & Publisher at Scientific American explains: “Over 700 studies substantiate the notion that great oral health habits can be a simple step in improving one’s overall health. It’s proven that periodontitis increasingly poses a significant risk to the development and progression of multiple systemic conditions and gum disease is the mouth’s way of warning us of potentially more serious issues to come, so it’s important to heed those early warnings.”

While warning signs can be as small as bleeding gums or even tooth loss, they can lead to more severe conditions such as heightened pregnancy complications, cognitive loss, poor diabetes control, and increases the risk of cardiovascular disease.

SYSTEMIC SPREAD OF PLAQUE BACTERIA THROUGHOUT THE BODY

A healthy mouth has minimal plaque build-up, ensuring oral bacteria cannot multiply, cause cavities, gum deterioration or spread beyond the mouth. However, when plaque build-up is present around the gum line and between teeth, it shelters oral bacteria (including P.gingivalis) from your toothbrush and natural defences. This provides the perfect conditions for the bacteria to thrive and cause inflammation-causing toxins that are known to spread throughout the rest of the body.

The formation of gum disease begins when plaque containing millions of bacteria coats the teeth, accumulates undisturbed. Acid produced by the bacteria can erode tooth enamel causing cavities and irritate the gums and cause gingivitis which can progress into periodontitis – a more serious infection that can lead to tooth loss.

When oral conditions worsen, the hidden plaque bacteria can cause an inflammatory response in the periodontal tissues that sets off a chain reaction, spreading systemically through the body via the circulatory system to other parts of the body. These oral bacteria are also found to be transmitted via the lungs and gastrointestinal tract.

DISEASES IMPACTED BY GUM DISEASE

  1. StrokePeriodontitis may increase the risk for stroke. A continuous flow of bacteria into the bloodstream from exacerbated gum sites can trigger inflammation, prompting plaque growth and leading to blood clots.ii
  2. Diabetes - There is a two-way relationship between diabetes and periodontitis, with more severe periodontal tissue destruction observed in diabetic populations , due to poorly controlled glucose levels.iii iv
  3. Heart disease - Patients with periodontal disease are at increased risk for cardiovascular disease. Chronic gum inflammation may cause bad bacteria and toxins to enter the bloodstream and circulate to plaque sites in arterial walls.v
  4. Pregnancy gingivitis - Pregnant women are at increased risk of gingivitis and pregnant women with periodontitis are at increased risk for adverse pregnancy outcomes , including pre-term birth, low birth weight babies, and pregnancy hypertension (pre-eclampsia).vi
  5. Dementia - Patients with Alzheimer’s Disease and cognitive function loss have a higher risk for developing poor oral hygiene and periodontal disease. The relationship is bi-directional , as periodontal bacteria can also infect the brain and play a direct role in the build-up of amyloid brain lesions, leading to Alzheimer’s disease.vii

MAINTAINING A HEALTHY MOUTH AND BODY

Oral-B, the No.1 Dentist Recommended Toothbrush Brand Worldwide, is on a mission to make the invisible connection between oral health and whole-body wellness visible and to empower people to take their health into their own hands.

Following a daily holistic Oral-B regimen can help with maintaining a happy, healthy mouth:

  • Electric Toothbrush with a Round-Head
    Oral-B brushes are round for a reason, to adapt to each individual tooth and reach between the teeth. The Oral-B iO’s revolutionary technology removes 100% more plaque than a manual brush to give you that professional clean feeling every single day.
  • Stannous Fluoride Toothpaste
    Stannous Fluoride (SnF2) helps to protect your gums against bacterial plaque.
  • Mouth Rinse
    Mouth rinses containing bioavailable Cetylpyridinium Chloride (CPC) formulated at 0.07% helps to reduce plaque.
  • Interdental Cleaning
    Plaque easily accumulates and hides between teeth where toothbrushing can’t reach. Regular cleaning between teeth helps to remove plaque and helps protect gums.
  • Regular Oral-Health Check-Ups
    Partner with your dental professional regularly to prevent and detect signs of gum infection at its earliest stages.

Scientific American educational resources developed in partnership with Oral B can be found here.

####

About Oral-B

Oral-B® exists to help people Brush Like a Pro. Oral-B® was founded in 1950 by Dr. Robert Hutson, a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Artificial Intelligencery®, Febreze®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.


i Oral Health https://www.who.int/news-room/fact-sheets/detail/oral-health (Accessed April 2021)

ii Janket SJ, Baird AE, Chuang SK, Jones JA. Meta- analysis of periodontal disease and risk for coronary heart disease and stroke. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95:559-569

iii Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: A two-way relationship. Ann Periodontol 1998;3:51-61

iv Preshaw PM, Alba AL, Jepsen S, Konstantinidis A, Makrilakis K, Taylor R. Periodontitis and diabetes: A two-way relationship. Diabetologia 2012;55:21-31.

v Blaizot A, Vergenes JN, Nuwwareh S, Amar J, Sixou M. Periodontal diseases and cardiovascular events: Meta-analyseis of observational studies. Int Dent J 2009; 59(4):197-209

vi Daalderop LD,Wieland BV, Tomsin K, Reyes L, Kramer BW, Vanterpool SF. Periodontal disease and pregnancy outcomes: Overview of systematic reviews. JDR Clinl Transl Res 2018;3:10-27. | Manrique-Corredor EJ, Orozco-Beltran D, Lopez-Pineda A, Quesada JA, Gil-Guillen VF, Carratala-Munuera C. Maternal periodontitis and preterm birth: systematic review and meta-analysis. Community Dent Oral Epidemiol 2019;47:243-251. | Chambrone L, Guglielmetti MR, Pannati CM, Chambrone LA. Evidence grade associating periodontitis to preterm birth and/or low birth weight: I. A systematic review of prospective cohort studies. J Clin Periodontol 2011;38:795-808. | Wei BJ, Chen YJ, Wu B. Periodontal disease and risk of preeclampsia: A meta- analysis of observational studies. PLOS ONE 2013;8:1-6. | Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: Systematic review and meta-analysis. Am J Obstet Gynecol. 2008;Jan:7-22

vii Savitt ED, Socransky SS. Distribution of certain subgingival microbial species in selected periodontal conditions. J Periodontal Res 1984, 19 (2): 111-123.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zayed Sustainability Prize Opens Global Call for Submissions for 2027 Cycle26.1.2026 16:25:00 CET | Press release

With an increased prize fund of US $7.2 million, the Zayed Sustainability Prize supports enterprises, nonprofit organisations and schools delivering transformative solutions.Entries are now open, with applicants invited to submit innovative, scalable sustainability solutions.Now in its 18th year, the Prize has positively impacted over 400 million people by expanding access to clean energy, water, food, healthcare and improving climate resilience. The Zayed Sustainability Prize, an affiliate of Erth Zayed Philanthropies and the UAE’s pioneering global award for sustainability and humanitarian innovation, has opened submissions for its 2027 cycle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126912976/en/ Winners of the 2026 Zayed Sustainability Prize (Photo: AETOSWire) The Prize carries forward the vision and legacy of the UAE’s founding father, Sheikh Zayed bin Sultan Al Nahyan, by supporting those advancing a more incl

2026 Japan Prize: Two U.S. Scientists and One Japanese Scientist Awarded26.1.2026 15:00:00 CET | Press release

Presentation Ceremony to Take Place in Tokyo in April The Japan Prize Foundation announced the winners of the 2026 Japan Prize at 1:00 p.m. on 21 January 2026. Prof. Cynthia Dwork (USA) has been awarded the Japan Prize in the field of Electronics, Information, and Communication. Prof. Shizuo Akira (Japan) and Prof. Zhijian "James" Chen (USA) have been awarded the Japan Prize in the field of Life Sciences. For this year’s Japan Prize, Prof. Dwork is being recognized for her Contribution to leading research for building an ethical digital society, including differential privacy and fairness. Prof. Akira and Prof. Chen are being recognized for their Discovery of the nucleic acid sensing mechanism by the innate immune system. For the 2026 Japan Prize, the Foundation asked approximately 16,000 prominent scientists and engineers from around the world to nominate researchers working in this year’s fields. We received 107 nominations for the field of Electronics, Information, and Communication

Uzbekistan, the Engine of Central Asia: GDP Above USD 145 Billion and Exports Rising to USD 33.4 Billion – Embassy of the Republic of Uzbekistan in Italy26.1.2026 14:31:00 CET | Press release

With a GDP exceeding USD 145 billion, exports of USD 33.4 billion up 23 percent, and gold reserves surpassing USD 60 billion, Uzbekistan enters 2026 with solid and steadily strengthening macroeconomic indicators. The Embassy of the Republic of Uzbekistan in Italy claims that the climate of confidence, reaffirmed in the State of the Nation Address delivered on 26 December by President Shavkat Mirziyoyev, is reflected in international trade data: total foreign investment has reached USD 43.1 billion, equal to 31.9 percent of GDP. This trajectory has also contributed to an improvement in the country’s sovereign rating, upgraded to BB by the leading international rating agencies. For the current year, the Government forecasts economic growth of 6.6 percent, with GDP estimated at USD 167 billion. A total of 782 new industrial and infrastructure projects will be launched, with an overall value of USD 52 billion, including 228 large production facilities as early as next year. The focus will

Lucend, Formerly Coolgradient, Raises $3.3M to Bring Transparent AI to Data Centers to Increase Uptime and Reliability While Maximizing Efficiency26.1.2026 14:00:00 CET | Press release

Lucend Seed round led by Remarkable Ventures Climate (RVC) to bring Transparent AI insights to data center operators in the U.S. increasing operational efficiency by 40% Lucend today announced that it is bringing its transparent data center optimization to the U.S. market, helping enterprises illuminate complex operational environments and empowering data center operators, innovation officers, and sustainability officers with the intelligence they need to act with trust, accuracy, and confidence. Lucend’s Transparent AI platform connects to existing infrastructure, no new hardware required, to transform static systems into adaptive, self-learning environments. The software takes existing sensor data to see connections across 300 billion sensor readings. Lucend’s AI analyzes billions of data points daily and provides prescriptive recommendations. The intelligence that Lucend’s platform delivers “shows its work,” empowering operators and delivering verifiable impact across enterprise env

Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis26.1.2026 14:00:00 CET | Press release

Study could lead to first-ever topical steroid-free treatment for the inner eye disease non-infectious anterior uveitis (NIAU) The study builds on ocular pharmacokinetic models demonstrating delivery after topical application and on animal models of experimental uveitis demonstrating pharmacological effects Novaliq is expanding with this proof-of-concept study into retina and inner-eye diseases as targeted topical delivery of EyeSol®-based drugs allowing to develop breakthrough therapies Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases. NOV05, tacrolimus ophthalmic solution in EyeSol®, is a unique, steroid-free topical anti-inflammatory treatment. The IND clearance enables initiation of the EYETAC Pha

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye